Business Context and Reporting Period
Company: pSivida Limited (Note: The input metadata references "Eyepoint, Inc.", but the filing text is for pSivida Limited, a drug delivery company incorporated in Western Australia).
Reporting Period: Fiscal year ended June 30, 2007.
Business Overview: pSivida is a development-stage biotechnology company focused on proprietary drug delivery technologies: Durasert (ophthalmic implants), BioSilicon (oncology and drug delivery), and CODRUG (simultaneous drug release). The company has no internal sales force and relies on strategic collaborations with partners such as Bausch & Lomb, Alimera Sciences, and Pfizer. Key products include Vitrasert and Retisert (licensed to Bausch & Lomb) and Medidur (in Phase III trials with Alimera).
Regulatory Status: Following a share issuance in July 2007, the company ceased to be a Foreign Private Issuer (FPI) and will comply with U.S. domestic issuer reporting requirements (Form 10-K/10-Q) starting in fiscal 2008.
Key Financial Metrics (A-IFRS)
| Metric | 2007 (A$'000) | 2006 (A$'000) |
|---|---|---|
| Revenue | 2,282 | 1,393 |
| Net Loss | (122,258) | (28,166) |
| Loss Per Share (Basic/Diluted) | (0.27) | (0.09) |
| Total Assets | 101,554 | 235,486 |
| Cash and Cash Equivalents | 3,146 | 15,447 |
| Long-term Debt | 0 | 3,940 |
| Net Assets (Equity) | 77,720 | 175,033 |
Note: Financial statements are presented in Australian Dollars (A$). Exchange rate at June 30, 2007: US$0.8491 = A$1.00.
Material Changes vs. Prior Period
- Significant Net Loss Increase: Net loss increased by 334% to A$122.3 million (from A$28.2 million in 2006). This was primarily driven by non-cash charges.
- Intangible Asset Impairments: The company recorded A$94.4 million in impairment charges related to Retisert patents and BrachySil product candidates due to reduced sales expectations and clinical trial delays.
- Debt Extinguishment: A loss of A$28.2 million was recorded on the extinguishment of convertible notes (Sandell and Absolute notes) which were fully redeemed during the year.
- Revenue Growth: Revenue increased 69% to A$2.3 million, driven by higher royalty income from Bausch & Lomb (Retisert) and collaborative research funding.
- Cash Position: Cash and cash equivalents declined significantly from A$15.4 million to A$3.1 million due to operating losses and debt repayments, though a July 2007 equity raise improved liquidity post-period.
Guidance, Outlook, and Risks
Liquidity and Capital Needs: The company stated that existing cash resources (including proceeds from a July 2007 share issue of approx. A$21 million) are sufficient to fund operations through at least June 30, 2008. However, additional funding will be required prior to that date to continue current operations and product development. Failure to raise capital could force significant scaling back of operations.
Outlook: The company expects to continue incurring net losses through at least fiscal 2010. Future profitability depends on the commercial success of Medidur and BrachySil, as well as royalty income from Retisert. Royalty income from Retisert is expected to decrease substantially in the near term due to an advance royalty agreement with Bausch & Lomb.
Key Risks and Contingencies:
- Going Concern: Recurring losses and negative cash flows raise substantial doubt about the ability to continue as a going concern without additional financing.
- Internal Controls: Management identified a material weakness in internal control over financial reporting due to inadequate accounting personnel trained in complex transactions.
- Regulatory Approval: Commercialization depends on FDA and foreign regulatory approvals for Medidur and BrachySil, which are not guaranteed.
- Collaboration Dependence: The company relies heavily on partners (Bausch & Lomb, Alimera, Pfizer) for development and commercialization; termination of these agreements would be materially adverse.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the A$21 million raised in July 2007 to cover operating expenses through June 2008, given the high burn rate.
- Retisert Royalties: Confirm the timeline for when the advance royalty agreement with Bausch & Lomb will be satisfied and full royalty payments will resume.
- Medidur Clinical Trials: Monitor the progress and results of the Phase III trials for Medidur (Diabetic Macular Edema) conducted by Alimera Sciences.
- BrachySil Development: Assess the status of the Phase IIa pancreatic cancer trial and the decision to place the liver cancer trial on hold.
- Internal Control Remediation: Review the company's progress in addressing the material weakness in financial reporting controls.
- Future Financing: Evaluate the likelihood and terms of future equity or debt offerings required to fund operations beyond mid-2008.